VivoSeq
Oncology

Advanced Solid Tumor Cancer

2

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

Advanced Solid Tumor Cancer is an early-stage landscape with 2 programs across 2 companies. The most active players are BioNTech, BeiGene.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

11/100

Mech. Concentration

100/100

Completion Rate

67/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

BioNTech logo

BioNTech

1 program

PreclinicalBeiGene logo

BeiGene

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical2

Tislelizumab

BeiGene

BNT3214

BioNTech

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

2programs
Small molecule150%
Monoclonal antibody150%

Modality classified for 100% of 2 pipeline programs.

Analysis

Trial Status

5

clinical trials

Completed2 · 40%
Terminated1 · 20%
Not yet recruiting1 · 20%
Recruiting1 · 20%

Clinical Trials

Trial Activity

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.
Completed·—·Phase 2·NCT02272998·22 enrolled
Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease
Terminated·VVirginia Commonwealth University·Phase 1·NCT01427322·6 enrolled
Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer
Completed·AAmMax Bio, Inc.·Phase 1/2·NCT02713529·117 enrolled
Phase Ib/II Study of Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease (TIBEC)
Not yet recruiting·NNational University Hospital, Singapore·Preclinical·NCT07681297·154 enrolled
A Phase I/IIa, First-in-human, Open-label, Multi-site, Multi-regional, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors
Recruiting·BioNTech logoBioNTech·Preclinical·NCT07455734·533 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)